Guidelines, Position Statements, Evidence Assessments and Consensus Opinions


Andrew C. Charles MD, Kathleen B. Digre MD, Peter J. Goadsby MD, PhD, Matthew S. Robbins MD, Andrew Hershey MD, PhD, The American Headache Society. (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.


Jessica Ailani MDRebecca C. Burch MDMatthew S. Robbins MDon behalf of the Board of Directors of the American Headache Society. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.


Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. (2019) Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.


Digre, K.., American Headache Society


Pringsheim, T., Davenport, W. J., Marmura, M. J., Schwedt, T. J. and Silberstein, S. (2016), How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache, 56: 1194–1200. doi:10.1111/head.12870

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016 Jul;56(7):1093-106. doi: 10.1111/head.12866.

Orr, S. L., Friedman, B. W., Christie, S., Minen, M. T., Bamford, C., Kelley, N. E. and Tepper, D. (2016), Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache: The Journal of Head and Face Pain, 56: 911–940. doi:10.1111/head.12835


Marmura MJ1, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499.


Loder, E., Weizenbaum, E., Frishberg, B., Silberstein, S. and American Headache Society Choosing Wisely Task Force (2013), Choosing Wisely in Headache Medicine: The American Headache Society’s List of Five Things Physicians and Patients Should Question. Headache: The Journal of Head and Face Pain, 53: 1651–1659. doi:10.1111/head.12233


Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun;52(6):930-45. doi: 10.1111/j.1526-4610.2012.02185.x.


Evans, R. W., Tepper, S. J., Shapiro, R. E., Sun-Edelstein, C. and Tietjen, G. E. (2010), The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin-Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper. Headache: The Journal of Head and Face Pain, 50: 1089–1099. doi:10.1111/j.1526-4610.2010.01691.x


Penzien, D. B., Andrasik, F., Freidenberg, B. M., Houle, T. T., Lake, A. E., Lipchik, G. L., Holroyd, K. A., Lipton, R. B., McCrory, D. C., Nash, J. M., Nicholson, R. A., Powers, S. W., Rains, J. C. and Wittrock, D. A. (2005), Guidelines for Trials of Behavioral Treatments for Recurrent Headache, First Edition: American Headache Society Behavioral Clinical Trials Workgroup. Headache: The Journal of Head and Face Pain, 45: S110–S132. doi:10.1111/j.1526-4610.2005.4502004.x


Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K.Michael., Goadsby, P. J., Hahn, S., Hutchinson, S., Matchar, D., Silberstein, S., Smith, T. R., Purdy, R. A., Saiers, J. and The Triptan Cardiovascular Safety Expert Panel (2004), Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine. Headache: The Journal of Head and Face Pain, 44: 414–425. doi:10.1111/j.1526-4610.2004.04078.x